329 related articles for article (PubMed ID: 8187237)
1. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator.
Anglés-Cano E; Hervio L; Rouy D; Fournier C; Chapman JM; Laplaud M; Koschinsky ML
Chem Phys Lipids; 1994 Jan; 67-68():369-80. PubMed ID: 8187237
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments.
Rouy D; Koschinsky ML; Fleury V; Chapman J; Anglés-Cano E
Biochemistry; 1992 Jul; 31(27):6333-9. PubMed ID: 1627572
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu.
Rouy D; Grailhe P; Nigon F; Chapman J; Anglés-Cano E
Arterioscler Thromb; 1991; 11(3):629-38. PubMed ID: 1827591
[TBL] [Abstract][Full Text] [Related]
4. Overview on fibrinolysis: plasminogen activation pathways on fibrin and cell surfaces.
Anglés-Cano E
Chem Phys Lipids; 1994 Jan; 67-68():353-62. PubMed ID: 8187235
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of novel lysine-independent apolipoprotein(a)-binding sites in fibrin(ogen) alphaC-domains.
Tsurupa G; Ho-Tin-Noé B; Anglés-Cano E; Medved L
J Biol Chem; 2003 Sep; 278(39):37154-9. PubMed ID: 12853452
[TBL] [Abstract][Full Text] [Related]
6. Lp(a) particles mold fibrin-binding properties of apo(a) in size-dependent manner: a study with different-length recombinant apo(a), native Lp(a), and monoclonal antibody.
Kang C; Dominguez M; Loyau S; Miyata T; Durlach V; Anglés-Cano E
Arterioscler Thromb Vasc Biol; 2002 Jul; 22(7):1232-8. PubMed ID: 12117743
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein(a), fibrin binding, and plasminogen activation.
Loscalzo J; Weinfeld M; Fless GM; Scanu AM
Arteriosclerosis; 1990; 10(2):240-5. PubMed ID: 2138452
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of fibrinolysis by lipoprotein(a).
Anglés-Cano E; de la Peña Díaz A; Loyau S
Ann N Y Acad Sci; 2001; 936():261-75. PubMed ID: 11460483
[TBL] [Abstract][Full Text] [Related]
9. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?
Hervio L; Chapman MJ; Thillet J; Loyau S; Anglés-Cano E
Blood; 1993 Jul; 82(2):392-7. PubMed ID: 8329699
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of Apo(a) kringle IV-10 and plasminogen kringles on the interactions of lipoprotein(a) with regulatory molecules.
Xue S; Green MA; LoGrasso PV; Boettcher BR; Madison EL; Curtiss LK; Miles LA
Thromb Haemost; 1999 Mar; 81(3):428-35. PubMed ID: 10102473
[TBL] [Abstract][Full Text] [Related]
11. Baboon lipoprotein(a) binds very weakly to lysine-agarose and fibrin despite the presence of a strong lysine-binding site in apolipoprotein(a) kringle IV type 10.
Belczewski AR; Ho J; Taylor FB; Boffa MB; Jia Z; Koschinsky ML
Biochemistry; 2005 Jan; 44(2):555-64. PubMed ID: 15641780
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces.
Hancock MA; Boffa MB; Marcovina SM; Nesheim ME; Koschinsky ML
J Biol Chem; 2003 Jun; 278(26):23260-9. PubMed ID: 12697748
[TBL] [Abstract][Full Text] [Related]
13. Molecular cloning of the cDNA encoding the carboxy-terminal domain of chimpanzee apolipoprotein(a): an Asp57 --> Asn mutation in kringle IV-10 is associated with poor fibrin binding.
Chenivesse X; Huby T; Wickins J; Chapman J; Thillet J
Biochemistry; 1998 May; 37(20):7213-23. PubMed ID: 9585533
[TBL] [Abstract][Full Text] [Related]
14. Evidence that the fibrinogen binding domain of Apo(a) is outside the lysine binding site of kringle IV-10: a study involving naturally occurring lysine binding defective lipoprotein(a) phenotypes.
Klezovitch O; Edelstein C; Scanu AM
J Clin Invest; 1996 Jul; 98(1):185-91. PubMed ID: 8690792
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein(a): a kinetic study of its influence on fibrin-dependent plasminogen activation by prourokinase or tissue plasminogen activator.
Liu JN; Harpel PC; Pannell R; Gurewich V
Biochemistry; 1993 Sep; 32(37):9694-700. PubMed ID: 8373773
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site.
Ahn JH; Lee HJ; Lee EK; Yu HK; Lee TH; Yoon Y; Kim SJ; Kim JS
Biol Chem; 2011 Apr; 392(4):347-56. PubMed ID: 21194375
[TBL] [Abstract][Full Text] [Related]
17. Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation.
Martínez C; Rivera J; Loyau S; Corral J; González-Conejero R; Lozano ML; Vicente V; Anglés-Cano E
Thromb Haemost; 2001 Apr; 85(4):686-93. PubMed ID: 11341506
[TBL] [Abstract][Full Text] [Related]
18. Multiple binding with identical linkage: a mechanism that explains the effect of lipoprotein(a) on fibrinolysis.
Hervio L; Durlach V; Girard-Globa A; Anglés-Cano E
Biochemistry; 1995 Oct; 34(41):13353-8. PubMed ID: 7577920
[TBL] [Abstract][Full Text] [Related]
19. Antifibrinolytic effect of single apo(a) kringle domains: relationship to fibrinogen binding.
Rahman MN; Petrounevitch V; Jia Z; Koschinsky ML
Protein Eng; 2001 Jun; 14(6):427-38. PubMed ID: 11477223
[TBL] [Abstract][Full Text] [Related]
20. Molecular assembly of plasminogen and tissue-type plasminogen activator on an evolving fibrin surface.
Fleury V; Loyau S; Lijnen HR; Nieuwenhuizen W; Anglés-Cano E
Eur J Biochem; 1993 Sep; 216(2):549-56. PubMed ID: 8375393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
